These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 37316101)

  • 1. Artificial intelligence and statistical methods for stratification and prediction of progression in amyotrophic lateral sclerosis: A systematic review.
    Tavazzi E; Longato E; Vettoretti M; Aidos H; Trescato I; Roversi C; Martins AS; Castanho EN; Branco R; Soares DF; Guazzo A; Birolo G; Pala D; Bosoni P; Chiò A; Manera U; de Carvalho M; Miranda B; Gromicho M; Alves I; Bellazzi R; Dagliati A; Fariselli P; Madeira SC; Di Camillo B
    Artif Intell Med; 2023 Aug; 142():102588. PubMed ID: 37316101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model-Based and Model-Free Techniques for Amyotrophic Lateral Sclerosis Diagnostic Prediction and Patient Clustering.
    Tang M; Gao C; Goutman SA; Kalinin A; Mukherjee B; Guan Y; Dinov ID
    Neuroinformatics; 2019 Jul; 17(3):407-421. PubMed ID: 30460455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Artificial intelligence for screening and diagnosis of amyotrophic lateral sclerosis: a systematic review and meta-analysis.
    Umar TP; Jain N; Papageorgakopoulou M; Shaheen RS; Alsamhori JF; Muzzamil M; Kostiks A
    Amyotroph Lateral Scler Frontotemporal Degener; 2024 Aug; 25(5-6):425-436. PubMed ID: 38563056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying and predicting amyotrophic lateral sclerosis clinical subgroups: a population-based machine-learning study.
    Faghri F; Brunn F; Dadu A; ; ; Zucchi E; Martinelli I; Mazzini L; Vasta R; Canosa A; Moglia C; Calvo A; Nalls MA; Campbell RH; Mandrioli J; Traynor BJ; Chiò A
    Lancet Digit Health; 2022 May; 4(5):e359-e369. PubMed ID: 35341712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using an onset-anchored Bayesian hierarchical model to improve predictions for amyotrophic lateral sclerosis disease progression.
    Karanevich AG; Statland JM; Gajewski BJ; He J
    BMC Med Res Methodol; 2018 Feb; 18(1):19. PubMed ID: 29409450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials.
    Witzel S; Frauhammer F; Steinacker P; Devos D; Pradat PF; Meininger V; Halbgebauer S; Oeckl P; Schuster J; Anders S; Dorst J; Otto M; Ludolph AC
    Transl Neurodegener; 2021 Aug; 10(1):31. PubMed ID: 34433481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model.
    Westeneng HJ; Debray TPA; Visser AE; van Eijk RPA; Rooney JPK; Calvo A; Martin S; McDermott CJ; Thompson AG; Pinto S; Kobeleva X; Rosenbohm A; Stubendorff B; Sommer H; Middelkoop BM; Dekker AM; van Vugt JJFA; van Rheenen W; Vajda A; Heverin M; Kazoka M; Hollinger H; Gromicho M; Körner S; Ringer TM; Rödiger A; Gunkel A; Shaw CE; Bredenoord AL; van Es MA; Corcia P; Couratier P; Weber M; Grosskreutz J; Ludolph AC; Petri S; de Carvalho M; Van Damme P; Talbot K; Turner MR; Shaw PJ; Al-Chalabi A; Chiò A; Hardiman O; Moons KGM; Veldink JH; van den Berg LH
    Lancet Neurol; 2018 May; 17(5):423-433. PubMed ID: 29598923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Dynamic Bayesian Network model for the simulation of Amyotrophic Lateral Sclerosis progression.
    Zandonà A; Vasta R; Chiò A; Di Camillo B
    BMC Bioinformatics; 2019 Apr; 20(Suppl 4):118. PubMed ID: 30999865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deep learning methods to predict amyotrophic lateral sclerosis disease progression.
    Pancotti C; Birolo G; Rollo C; Sanavia T; Di Camillo B; Manera U; Chiò A; Fariselli P
    Sci Rep; 2022 Aug; 12(1):13738. PubMed ID: 35962027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of spirometric tests in Amyotrophic Lateral Sclerosis patients.
    Pirola A; De Mattia E; Lizio A; Sannicolò G; Carraro E; Rao F; Sansone V; Lunetta C
    Clin Neurol Neurosurg; 2019 Sep; 184():105456. PubMed ID: 31382080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis.
    Witzel S; Maier A; Steinbach R; Grosskreutz J; Koch JC; Sarikidi A; Petri S; Günther R; Wolf J; Hermann A; Prudlo J; Cordts I; Lingor P; Löscher WN; Kohl Z; Hagenacker T; Ruckes C; Koch B; Spittel S; Günther K; Michels S; Dorst J; Meyer T; Ludolph AC;
    JAMA Neurol; 2022 Feb; 79(2):121-130. PubMed ID: 35006266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Creatine for amyotrophic lateral sclerosis/motor neuron disease.
    Pastula DM; Moore DH; Bedlack RS
    Cochrane Database Syst Rev; 2010 Jun; (6):CD005225. PubMed ID: 20556761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of amyotrophic lateral sclerosis in Lebanon-a chart review.
    Malek E; Ismail H; Doumiati H; Salameh J
    Amyotroph Lateral Scler Frontotemporal Degener; 2020 Nov; 21(7-8):614-619. PubMed ID: 32633637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracellular Vesicles as Potential Biomarkers in Amyotrophic Lateral Sclerosis.
    Barbo M; Ravnik-Glavač M
    Genes (Basel); 2023 Jan; 14(2):. PubMed ID: 36833252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic Alteration and Amyotrophic Lateral Sclerosis Outcome: A Systematic Review.
    Brito MD; da Silva GFG; Tilieri EM; Araujo BG; Calió ML; Rosenstock TR
    Front Neurol; 2019; 10():1205. PubMed ID: 31824397
    [No Abstract]   [Full Text] [Related]  

  • 17. Development and Validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS).
    Fournier CN; Bedlack R; Quinn C; Russell J; Beckwith D; Kaminski KH; Tyor W; Hertzberg V; James V; Polak M; Glass JD
    JAMA Neurol; 2020 Apr; 77(4):480-488. PubMed ID: 31886839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic Review and Meta-Analyses of Aminopeptidases as Prognostic Biomarkers in Amyotrophic Lateral Sclerosis.
    Teruel-Peña B; Gómez-Urquiza JL; Suleiman-Martos N; Prieto I; García-Cózar FJ; Ramírez-Sánchez M; Fernández-Martos C; Domínguez-Vías G
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What do you think caused your ALS? An analysis of the CDC national amyotrophic lateral sclerosis patient registry qualitative risk factor data using artificial intelligence and qualitative methodology.
    Boyce D; Raymond J; Larson TC; Kirkland E; Horton DK; Mehta P
    Amyotroph Lateral Scler Frontotemporal Degener; 2024 Aug; 25(5-6):615-624. PubMed ID: 38717430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Artificial intelligence in neurodegenerative disease research: use of IBM Watson to identify additional RNA-binding proteins altered in amyotrophic lateral sclerosis.
    Bakkar N; Kovalik T; Lorenzini I; Spangler S; Lacoste A; Sponaugle K; Ferrante P; Argentinis E; Sattler R; Bowser R
    Acta Neuropathol; 2018 Feb; 135(2):227-247. PubMed ID: 29134320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.